Posted in WP-12

Daily Mail columnists discard journalism for propaganda about Labour Government’s climate and energy policies – part 1 – The London School of Economics and Political Science

Daily Mail columnists discard journalism for propaganda about Labour Government’s climate and energy policies – part 1  The London School of Economics and Political Science Source link Daily Mail columnists discard journalism for propaganda about Labour Government’s climate and energy policies – part 1 – The London School of Economics and Political Science #Daily #Mail #columnists …

Read More

Continue Reading... Daily Mail columnists discard journalism for propaganda about Labour Government’s climate and energy policies – part 1 – The London School of Economics and Political Science
Posted in WP-12

NOAA, Biden-Harris Administration announce $75.6 million for Washington state projects as part of Investing in America Agenda – National Oceanic and Atmospheric Administration

NOAA, Biden-Harris Administration announce $75.6 million for Washington state projects as part of Investing in America Agenda  National Oceanic and Atmospheric Administration Source link NOAA, Biden-Harris Administration announce $75.6 million for Washington state projects as part of Investing in America Agenda – National Oceanic and Atmospheric Administration #NOAA #BidenHarris #Administration #announce #million #Washington #state #projects #part …

Read More

Continue Reading... NOAA, Biden-Harris Administration announce $75.6 million for Washington state projects as part of Investing in America Agenda – National Oceanic and Atmospheric Administration
Posted in WP-12

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

CROSSJECT Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized loans France 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potential Dijon, France, July 10th, 2024 07:30 CET — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced …

Read More

Continue Reading... Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine